当前位置: X-MOL 学术Am. J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
American Journal of Clinical Oncology ( IF 1.6 ) Pub Date : 2021-06-09 , DOI: 10.1097/coc.0000000000000841
Weijie Ma 1, 2 , Zimu Gong 3 , Hamzah Abu-Sbeih 4 , Yuanzun Peng 5 , Frederick Peng 6 , Fangwen Zou 2, 7 , Aline Charabaty 8 , Pablo C Okhuysen 9 , Jennifer L McQuade 10 , Mehmet Altan 11 , Hao Chi Zhang 2 , Anusha S Thomas 2 , Yinghong Wang 2
Affiliation  

Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and outcome of IMDC remains unclear.

中文翻译:

具有叠加胃肠道感染的癌症患者的免疫检查点抑制剂相关腹泻或结肠炎的结果。

免疫介导的腹泻和结肠炎 (IMDC) 是接受免疫检查点抑制剂 (ICI) 的癌症患者的常见不良事件。胃肠道 (GI) 感染可与 IMDC 共同发生,其对 IMDC 病程和结果的影响尚不清楚。
更新日期:2021-06-11
down
wechat
bug